XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Long-Term Investments (Tables)
 9 Months Ended
Sep. 30, 2019
Schedule of ownership percentages of investee
  Ownership percentage    
   September 30,   December 31,   Accounting
Name of related party  2019   2018   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   9.71%   7.13%  Cost Method
BioFirst Corporation   16.14%   15.84%  Equity Method
Rgene Corporation   31.63%   31.62%  Equity Method
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business    
Braingenesis Biotechnology Co., Ltd.   No specific business relationship  
Genepharm Biotech Corporation   No specific business relationship  
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs  
BioFirst Corporation   Loaned from the investee and provides research and development support service  
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs  
Schedule of long-term investment
   September 30,
2019		   December 31,
2018		 
Non-marketable Cost Method Investments, net  (Unaudited)     
Braingenesis Biotechnology Co., Ltd.  $7,213   $7,213 
Genepharm Biotech Corporation   22,021    22,021 
BioHopeKing Corporation   1,926,067    1,956,429 
Sub total   1,955,301    1,985,663 
Equity Method Investments, net          
BioFirst Corporation   1,315,109    1,502,506 
Rgene Corporation   -    - 
Total  $3,270,410   $3,488,169 
Schedule of equity investments

   Nine Months Ended
September 30,		 
   2019   2018 
   (Unaudited) 
Share of equity method investee losses  $(182,113)  $(164,649)
Impairments   -    - 
Total losses on equity investments  $(182,113)  $(164,649)
BioFirst [Member]  
Schedule of balance sheets
   September 30,
 2019		  

December 31,

2018 

 
   (Unaudited)     
Current Assets  $1,239,738   $7,551,898 
Noncurrent Assets   7,243,928    1,608,460 
Current Liabilities   1,903,098    1,648,206 
Noncurrent Liabilities   25,880    - 
Shareholders' Equity   6,554,688    7,512,152 
Schedule of statements of operation
  Nine Months Ended
September 30,		 
   2019   2018 
   (Unaudited) 
Net sales  $32,235   $33,304 
Gross profit   5,048    6,590 
Net loss   (842,838)   (766,425)
Share of losses from investments accounted for using the equity method   (182,113)   (164,649)
Rgene [Member]  
Schedule of balance sheets
  

September 30,
2019

   December 31,
2018		 
   (Unaudited)     
Current Assets  $29,869   $98,168 
Noncurrent Assets   93,031    14,779 
Current Liabilities   324,694    261,685 
Noncurrent Liabilities   4,565    - 
Shareholders’ Equity (Deficit)   (206,359)   (148,738)
Schedule of statements of operation

   Nine Months Ended
September 30,		 
   2019   2018 
   (Unaudited) 
Net sales  $-   $- 
Gross Profit   -    - 
Net loss   (59,717)   (191,534)
Share of loss from investments accounted for using the equity method   -    N/A